Duncker Streett & CO Inc Vertex Pharmaceuticals Inc Transaction History
Duncker Streett & CO Inc
- $542 Million
- Q3 2024
A detailed history of Duncker Streett & CO Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Duncker Streett & CO Inc holds 7,328 shares of VRTX stock, worth $2.95 Million. This represents 0.63% of its overall portfolio holdings.
Number of Shares
7,328
Previous 6,425
14.05%
Holding current value
$2.95 Million
Previous $3.01 Million
13.18%
% of portfolio
0.63%
Previous 0.58%
Shares
7 transactions
Others Institutions Holding VRTX
# of Institutions
1,726Shares Held
221MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$10.8 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$9.32 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.58 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.76 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$3.62 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $103B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...